Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial - Scorecard - MDSpire

Efficacy and Safety of Deucravacitinib in Patients with Active Psoriatic Arthritis: Results from the Phase 3 POETYK PsA-2 Trial Over 52 Weeks

  • By

  • Philip J. Mease

  • Vinod Chandran

  • April W. Armstrong

  • Ricardo Blanco

  • Alexis Ogdie

  • Evan L. Siegel

  • Alice B. Gottlieb

  • Xiaofeng Zeng

  • Diamant Thaçi

  • Mitsumasa Kishimoto

  • Hendrik Schulze-Koops

  • Alan Kivitz

  • Eva Dokoupilová

  • Akimichi Morita

  • Eric M. Ruderman

  • Michael Plewinski

  • Kejia Wang

  • Caroline Sardinas

  • Eleni Vritzali

  • John Vaile

  • Atul Deodhar

  • July 20, 2026

Share

Clinical Scorecard: Efficacy and Safety of Deucravacitinib in Patients with Active Psoriatic Arthritis: Results from the Phase 3 POETYK PsA-2 Trial Over 52 Weeks

At a Glance

CategoryDetail
ConditionActive Psoriatic Arthritis
Key MechanismsSelective tyrosine kinase 2 inhibitor
Target PopulationPatients naive to biologic DMARDs or previously treated with TNF inhibitors
Care SettingPhase 3 clinical trial

Key Highlights

  • Deucravacitinib demonstrated significant efficacy in achieving ACR20 response at 52 weeks.
  • The study included a randomized, double-blind, placebo-controlled design.
  • Patients were treated with deucravacitinib 6 mg daily or apremilast 30 mg twice daily.
  • Safety profile assessed through comparison with placebo and apremilast.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of PsA should be based on clinical criteria and imaging as needed.

Management

  • Consider deucravacitinib for patients who are naive to biologic DMARDs or have previously received TNF inhibitors.

Monitoring & Follow-up

  • Monitor for efficacy and safety throughout the treatment duration.

Risks

  • Evaluate potential risks associated with tyrosine kinase inhibitors.

Patient & Prescribing Data

Patients with active PsA who have not previously received biologic DMARDs or have been treated with TNF inhibitors.

Clinical Best Practices

  • Utilize ACR response criteria for assessing treatment efficacy.
  • Incorporate patient history of previous treatments when considering therapy options.

Related Resources & Content

Original Source(s)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

  • by Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

  • July 20, 2026

Related Content

He Needs an Expensive Drug. A Copay Card Helped — Until It Didn’t. - KFF Health News

Efficacy Comparison of Cycling Versus Transitioning to IL-17 Inhibitors Following Initial TNF Inhibitor Failure in Psoriatic Arthritis: A Multicenter Real-World Analysis

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.